Literature DB >> 10458715

Ventricular pacing with premature excitation for treatment of hypertensive-cardiac hypertrophy with cavity-obliteration.

D A Kass1, C H Chen, M W Talbot, C E Rochitte, J A Lima, R D Berger, H Calkins.   

Abstract

BACKGROUND: Hypertensive left ventricular hypertrophy with supranormal systolic ejection and distal cavity obliteration (HHCO) can result in debilitating exertional fatigue and dyspnea. Dual-chamber pacing with ventricular preactivation generates discoordinate contraction, which can limit cavity obliteration and thereby increase potential ejection reserve. Accordingly, we hypothesized that pacing may improve exercise tolerance long-term in this syndrome. METHODS AND
RESULTS: Dual-chamber pacemakers were implanted in 9 patients with exertional dyspnea caused by HHCO. Intrinsic atrial rate was sensed, and ventricular preactivation was achieved by shortening the atrial-ventricular delay. Pacing was on or off for successive 3-month periods (randomized, double-blind, crossover design), followed by 6 additional pacing-on months. Metabolic exercise testing, quality-of-life assessment, and rest and dobutamine-stress echocardiographic/Doppler data were obtained. After 3 months of pacing-on, exercise duration rose from 324+/-133 to 588+/-238 s (mean+/-SD; P=0.001, with 7 of 9 patients improving >/=30%), and maximal oxygen consumption increased from 13.6+/-2.9 to 16.7+/-3.3 mL of O(2). min(-1). kg(-1) (P<0.02). Both parameters were little changed from baseline during the pacing-off period. Improved exercise capacity persisted at 1-year follow-up. Clinical symptoms and activities of daily living improved during the pacing-on period and stayed improved at 1 year, but they were little changed during the pacing-off period. Despite similar basal values, stroke volume (P<0.001) and cardiac output (P<0.02) increased with dobutamine stimulation 2 to 3 times more after 1 year of follow-up as compared with baseline.
CONCLUSIONS: Long-term dual-chamber pacing can improve exercise capacity, cardiac reserve, clinical symptoms, and activities of daily living in patients with HHCO. This therapy may provide a novel alternative for patients in whom traditional pharmacological treatment proves inadequate.

Entities:  

Mesh:

Year:  1999        PMID: 10458715     DOI: 10.1161/01.cir.100.8.807

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Exercise intolerance.

Authors:  Dalane W Kitzman; Leanne Groban
Journal:  Heart Fail Clin       Date:  2008-01       Impact factor: 3.179

Review 3.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Dual chamber pacing relieves obstruction in Japanese-variant hypertrophic cardiomyopathy.

Authors:  Omar Wever-Pinzon; Jorge Romero; Juan P Cordova
Journal:  Am J Ther       Date:  2013 Sep-Oct       Impact factor: 2.688

5.  Cardiac resynchronisation therapy in the presence of left-to-right intracardiac shunting: more good than harm?

Authors:  Kyu Kyu; Swee Chong Seow; Raymond Wong; Pipin Kojodjojo
Journal:  BMJ Case Rep       Date:  2016-03-17

6.  Exercise intolerance.

Authors:  Dalane W Kitzman; Leanne Groban
Journal:  Cardiol Clin       Date:  2011-08       Impact factor: 2.213

Review 7.  Mechanisms and efficacy of LV pre-excitation for patients with heart failure and supra-normal systolic function.

Authors:  D A Kass
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

8.  Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy.

Authors:  James W Malcolmson; Rebecca K Hughes; Abhishek Joshi; Jackie Cooper; Alexander Breitenstein; Matthew Ginks; Steffen E Petersen; Saidi A Mohiddin; Mehul B Dhinoja
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.